Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ernst, Tina, Aebi, Stefan, Zander, Andrea, Zander, Thilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996037/
https://www.ncbi.nlm.nih.gov/pubmed/35396243
http://dx.doi.org/10.1136/bcr-2021-246264
_version_ 1784684412324020224
author Ernst, Tina
Aebi, Stefan
Zander, Andrea
Zander, Thilo
author_facet Ernst, Tina
Aebi, Stefan
Zander, Andrea
Zander, Thilo
author_sort Ernst, Tina
collection PubMed
description BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-mutated melanoma, MEK and BRAF inhibition has been a successful approach. Here we describe a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in a patient with BRAF V600E-mutant refractory MM.
format Online
Article
Text
id pubmed-8996037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89960372022-04-27 Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance Ernst, Tina Aebi, Stefan Zander, Andrea Zander, Thilo BMJ Case Rep Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation) BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-mutated melanoma, MEK and BRAF inhibition has been a successful approach. Here we describe a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in a patient with BRAF V600E-mutant refractory MM. BMJ Publishing Group 2022-04-08 /pmc/articles/PMC8996037/ /pubmed/35396243 http://dx.doi.org/10.1136/bcr-2021-246264 Text en © BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Ernst, Tina
Aebi, Stefan
Zander, Andrea
Zander, Thilo
Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title_full Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title_fullStr Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title_full_unstemmed Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title_short Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
title_sort partial response to dabrafenib and trametinib in relapsed braf v600e-mutated multiple myeloma and possible mechanisms of resistance
topic Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996037/
https://www.ncbi.nlm.nih.gov/pubmed/35396243
http://dx.doi.org/10.1136/bcr-2021-246264
work_keys_str_mv AT ernsttina partialresponsetodabrafenibandtrametinibinrelapsedbrafv600emutatedmultiplemyelomaandpossiblemechanismsofresistance
AT aebistefan partialresponsetodabrafenibandtrametinibinrelapsedbrafv600emutatedmultiplemyelomaandpossiblemechanismsofresistance
AT zanderandrea partialresponsetodabrafenibandtrametinibinrelapsedbrafv600emutatedmultiplemyelomaandpossiblemechanismsofresistance
AT zanderthilo partialresponsetodabrafenibandtrametinibinrelapsedbrafv600emutatedmultiplemyelomaandpossiblemechanismsofresistance

Ejemplares similares